A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

• Status: Completed
• Trial end date: 2018-06-29

Summary

This study assessed the efficacy and safety of oral treatment with two dose levels of LDE225 in patients with locally advanced or metastatic BCC.

• Phase: Phase 2

Details

• Lead Sponsor: Novartis Pharmaceuticals